Australia - English - Department of Health (Therapeutic Goods Administration)

upside acquisitions pty ltd t/a upside nutrition - calcium pantothenate,inositol,rhodiola rosea -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - meningococcal polysaccharide group c, quantity: 5 microgram; meningococcal polysaccharide group y, quantity: 5 microgram; meningococcal polysaccharide group w135, quantity: 5 microgram; meningococcal polysaccharide group a, quantity: 5 microgram; tetanus toxoid, quantity: 44 microgram - injection, powder for - excipient ingredients: sucrose; trometamol hydrochloride - nimenrix is indicated for active immunisation of individuals from 6 weeks of age against invasive meningococcal diseases caused by neisseria meningitidis groups a, c, w-135 and y.

Singapore - English - HSA (Health Sciences Authority)

alcare pharmaceuticals pte ltd - general hospital - the upstream peripheral technologies ltd beback™ crossing catheter is intended to be used in conjunction with a steerable guidewire to access discrete regions of the peripheral vasculature. it may be used to facilitate placement and exchange of guidewires

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - meningococcal polysaccharide 48ug (4 µg of each of groups a, c, y & w-135, each separately conjugated to diphtheria toxoid, 48 µg total) - solution for injection - 4 µg each/0.5 ml - active: meningococcal polysaccharide 48ug (4 µg of each of groups a, c, y & w-135, each separately conjugated to diphtheria toxoid, 48 µg total) excipient: dibasic sodium phosphate monobasic sodium phosphate sodium chloride water for injection - menactra vaccine is indicated for active immunisation in individuals from 9 months through 55 years of age for the prevention of invasive meningococcal disease caused by n. meningitidis serogroups a, c, y and w-135. menactra vaccine is not indicated for the prevention of meningitis caused by other microorganisms or for the prevention of invasive meningococcal disease caused by n meningitidis serogroup b. menactra vaccine is not indicated for treatment of meningococcal infections. menactra vaccine is not indicated for immunisation against diphtheria.

United States - English - NLM (National Library of Medicine)

breakthrough products inc. - bismuth subsalicylate (unii: 62tey51rr1) (salicylic acid - unii:o414pz4lpz, bismuth cation - unii:zs9cd1i8ye) - bismuth subsalicylate 525 mg - upset stomach reliever/antidiarrheal relieves: - traveler's diarrhea - diarrhea - upset stomach due to overindulgence in food and drink, including: heartburn indigestion nausea gas belching fullness - heartburn - indigestion - nausea - gas - belching - fullness

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - meningococcal oligosaccharide group y, quantity: 5 microgram; meningococcal oligosaccharide group c, quantity: 5 microgram; diphtheria crm197 protein, quantity: 16 microgram; meningococcal oligosaccharide group w135, quantity: 5 microgram - injection, solution - excipient ingredients: sodium chloride; water for injections; monobasic sodium phosphate monohydrate; dibasic sodium phosphate dihydrate - menveo is indicated for active immunisation of infants and children (from 2 months of age), adolescents and adults to prevent invasive disease caused by neisseria meningitidis serogroups a, c, w-135 and y. the use of this vaccine should be in accordance with official recommendations.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

lexon (uk) ltd - hydrocortisone acetate; clotrimazole - cutaneous cream - 10mg/1gram ; 10mg/1gram

United States - English - NLM (National Library of Medicine)

safeway - bismuth subsalicylate (unii: 62tey51rr1) (bismuth cation - unii:zs9cd1i8ye) - upset stomach reliever and anti-diarrheal relieves: - diarrhea - heartburn - indigestion - nausea - upset stomach associated with these symptoms

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

crown healthcare (t) ltd, tanzania - sample cups -

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - meningococcal polysaccharide group w135, quantity: 10 microgram; meningococcal polysaccharide group c, quantity: 10 microgram; meningococcal polysaccharide group a, quantity: 10 microgram; meningococcal polysaccharide group y, quantity: 10 microgram - injection, solution - excipient ingredients: sodium acetate; tetanus toxoid; sodium chloride; water for injections - menquadfi is indicated for active immunisation for the prevention of invasive meningococcal disease caused by neisseria meningitidis serogroups a, c, w and y.,the use of menquadfi should be in accordance with official recommendations.